398 related articles for article (PubMed ID: 28717401)
1. Novel therapeutic strategies in the treatment of triple-negative breast cancer.
Oualla K; El-Zawahry HM; Arun B; Reuben JM; Woodward WA; Gamal El-Din H; Lim B; Mellas N; Ueno NT; Fouad TM
Ther Adv Med Oncol; 2017 Jul; 9(7):493-511. PubMed ID: 28717401
[TBL] [Abstract][Full Text] [Related]
2. Concepts and targets in triple-negative breast cancer: recent results and clinical implications.
Saha P; Nanda R
Ther Adv Med Oncol; 2016 Sep; 8(5):351-9. PubMed ID: 27583027
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
4. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook.
Obidiro O; Battogtokh G; Akala EO
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37513983
[TBL] [Abstract][Full Text] [Related]
5. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
6. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
[TBL] [Abstract][Full Text] [Related]
7. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
Tong L; Yu X; Wang S; Chen L; Wu Y
Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
[TBL] [Abstract][Full Text] [Related]
8. Triple-negative breast cancer: an unmet medical need.
Hudis CA; Gianni L
Oncologist; 2011; 16 Suppl 1():1-11. PubMed ID: 21278435
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
10. Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cao L; Niu Y
Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
[TBL] [Abstract][Full Text] [Related]
11. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
12. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
Yoder R; Kimler BF; Staley JM; Schwensen K; Wang YY; Finke K; O'Dea A; Nye L; Elia M; Crane G; McKittrick R; Pluenneke R; Madhusudhana S; Beck L; Shrestha A; Corum L; Marsico M; Stecklein SR; Godwin AK; Khan QJ; Sharma P
NPJ Breast Cancer; 2022 Jul; 8(1):80. PubMed ID: 35817765
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer: approved treatment options and their mechanisms of action.
Mandapati A; Lukong KE
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3701-3719. PubMed ID: 35976445
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
15. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
16. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
17. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
[TBL] [Abstract][Full Text] [Related]
18. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
20. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]